testing ayush

Strides Pharma Science Limited (Strides) stated that its wholly-owned step-down subsidiary, Strides Pharma Global Pte. Limited, Singapore, has secured the approval of the United States Food & Drug Administration (USFDA) for Prednisone Tablets USP, 1 mg. These tablets are a generic version of Schering Corporation’s Meticorten Tablets, 1 mg.

As per the IQVIA MAT July 2020 figures, the US market ranges up to USD 12 million for Prednisone Tablets USP, 1 mg. According to the company’s press release, the manufacturing of the tablet will take place at the flagship facility of the company at Bengaluru. The tablets will be sold in the US market by Strides Pharma Inc. 

Recently on August 21, 2020, Strides Pharma Science Limited got the USFDA approval for Ursodiol Tablets USP, 250 mg and 500 mg also. During February, Strides’ wholly-owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, signed a comprehensive asset transfer and licensing agreement with Pharmaceutics International, Inc. to obtain 18 ANDAs from the company for the US market. Strides aim to expand its niche offerings significantly on its front end, that will lead to multi fold growth in the upcoming years.

As per the consolidated unaudited financial reports of the company for the quarter ended June 30, 2020, the company’s total income was INR 7,941.02 million as compared to the INR 6,960.52 million of the corresponding quarter of the previous year. The profit before tax for the above-mentioned quarter stands at INR 1,051.25 million which is much higher than INR 248.84 million of the corresponding quarter of the previous year.

<< Back to Pharma News

Subscribe to PharmaTutor News Alerts by Email

Starpharma Holdings Limited has announced that it has entered into a new DEP® partnership with Chase Sun Pharmaceuticals to produce numerous DEP® nanoparticle formulations for an anti-infective drug. The deal also includes the possibility of carrying out additional DEP® programs, which may extend beyond anti-infective therapeutic areas.

Starpharma is an ASX 300 organization and a global pioneer in the production of dendrimer products for medicinal, life sciences and other applications. The company, headquartered in Melbourne in Australia, produces dendrimers that can be used to improve the properties of other drugs. The process is defined as drug delivery; the reason behind this is it seeks to ensure that a drug is delivered to the right area of the body at the correct time. This drug delivery technology is known as DEP®.

Earlier in September 2013, Starpharma Holdings Ltd and Gowan Company LLC had announced their partnership using Starpharma's Priostar® dendrimer technology in crop protection formulations. Starpharma’s Priostar® dendrimers were evaluated as and believed to be potential enhancements for certain Gowan products intended for high value markets under this deal. Now, with the help of their latest collaboration, Starpharma would be producing DEP® nanoparticle formulations for an anti-infective product for Chase Sun. They aim to boost its efficiency while also extending its medical value at the same time. Furthermore, under this deal Chase Sun will fund all activities and their associated expenses with the further advancement of any DEP® product. It is also reported that if in the future Chase Sun decides to market any of the subsequent DEP® products, a licensing deal specific to this technology would be signed with Starpharma. Chase Sun is China's top pharmaceutical firm which is focused on R&D and the marketing of healthcare goods. In addition, it operates in one of the largest markets in the world and has more than 60,000 employees.

The Starpharma CEO, Dr Jackie Fairley, stated in his comments that the company was delighted to enter in this new DEP® partnership with Chase Sun. Furthermore, he stated that this agreement highlights the broad applicability of the DEP® framework and will help DEP® expand its market potential in the anti-infectious environment.

<< Back to Pharma News

Subscribe to PharmaTutor News Alerts by Email

The Russian President Vladimir Putin has launched a coronavirus vaccine amid the global race to develop and distribute it. The world’s first vaccine comes even with the final stages of clinical trials to test efficiency and safety still going on.

The announcement came in the wake of the Covid-19 pandemic that has infected more than 20 million people and killed around 0.75 million people all over the world. It has also resulted in crippling world economies.

The Russian vaccine has been developed by the Gamaleya Institute in Moscow. The vaccine uses two strains of adenovirus that is known to cause mild cold in humans. Adenovirus vaccine is under trial in many other countries as well. The strains are genetically modified which can cause infected cells to create proteins from the spike of the coronavirus. This is a similar approach to a vaccine under development by AstraZeneca and Oxford University.

As per reports, Russia has dubbed the newly created vaccine “Sputnik V” after its Soviet satellite. Kirill Dmitriev, who is the head of the Russian Direct Investment Fund, an organization responsible for financing the vaccine project, announced that the Phase 3 trials would start by Wednesday. This means that mass production can be expected from September. He also mentioned that around 20 countries have already pre-ordered more than a billion doses.

Putin thanked everyone who has worked on the vaccine’s development and mentioned that this is a very important step for the world. He also hopes that the country’s research body should start the mass production of the vaccine very soon.

When talking about the vaccine, Putin mentions that it works effectively, helps build strong immunity, and has passed all the needed checks. He also added that one of his two daughters have received a shot of the vaccine and is doing well.

<< Back to Pharma News

Subscribe to PharmaTutor News Alerts by Email

The CEO & Chief Architect of Dokat, Inc, Ram Chella led a team to devise a fully Made in India Deep UV-C Air Sanitizer called as ‘Dokat Air’. This product has better germ-killing efficiency than any air purifier in the market because of its ‘Deep UV germicidal irradiation technology’ that helps to make indoors safer for people by killing disease-causing germs from the air.

It's a patent-pending novel product that can sanitize 1000-cubic feet of air within 15 minutes killing 99.99% germs. It's capable of killing various kinds of bacteria, viruses & molds like SARS, MERS, COVID-19, SARS-CoV-2 & Influenza Virus. The UV-C ray penetrates the cell of the micro-organisms and kills them by breaking their DNA. Having met international regulatory standards like ISO 9000:2015, FCC (US standard for electronic products) and European CE, this product helps in giving us an effective and efficient disinfecting solution to face the ongoing pandemic along with other numerous airborne diseases. This product is different from the regular air purifiers as it kills various kinds of disease-causing micro-organisms while filtering the air too. Regular air purifiers do not kill germs this well, instead, increases the germs’ spread. Here, comes the need for such a device that can sanitize the air while filtering pollutants along with.

Dokat-Air’s 100% UV leak proof ‘Germ Squash’ chamber uses the most effective broad-spectrum UV-C light and when the air passes through, it gives an optimal flow with maximum germicidal exposure, therefore making it better than the traditional  UV-C technology.

<< Back to Pharma News

Subscribe to PharmaTutor News Alerts by Email

• Read more about Momenta Enters Agreement With Johnson & Johnson

• Read more about Hyderabad to get Medtronic’s Largest Global R&D Centre Outside the USA

• Read more about AstraZeneca signs its first deal with Kangtai Bio to supply potential COVID-19 vaccine in China

• Read more about Traditions Health acquires Faith Hospice and Embrace Hospice